switching from semaglutide to tirzepatide dosage Guide In 2026 tirzepatide semaglutide dose conversion Switching

Studies are yet to confirm its effects in humans thoroughly

Zhang Y, Li X, Chen W, et al

Currently, both peptides are approved for MACE reduction based on the following data: The effectiveness of semaglutide for reducing MACE risk was studied in the SUSTAIN-6 trial, which included a total of 3297 diabetics, the majority of which had cardiovascular risks

Supported by rising interest in health-conscious diets Increased use in fortified beverages and snacks Strong demand from dietary supplements sector By Application, Functional Drinks Account for 42% of the Market Share The functional drinks category leads with a 42% share, attributed to expanding demand for energy beverages, sports recovery drinks, and weight-loss solutions

This means that its application will be misleading to an assay where rat serum is used as Ab-c